Morning Market Losers
Finisar (NASDAQ: FNSR) shares tumbled 23.56% to $19.30 after the company reported downbeat earnings for the fourth quarter and issued a weak profit forecast for the current quarter.
OncoMed Pharmaceuticals (NASDAQ: OMED) dropped 20.64% to $19.76 after the company voluntarily stopped enrollment for Phase 1 Vantictumab.
Cesca Therapeutics (NASDAQ: KOOL) declined 16.39% to $1.48 after the company priced priced 7.53 million share offering at $1.55 per share.
Oculus Innovative Sciences (NASDAQ: OCLS) fell 7.29% to $3.05 on Q4 results. The company's net income rose $9.9 million to $7.5 million in the quarter.
TG Therapeutics (NASDAQ: TGTX) shares declined 7.26% to $8.18 after the company's TG-1101 in combination with Ibrutinib showed a 90% response rate in patients with previously treated CLL and MCL.
Achillion Pharmaceuticals (NASDAQ: ACHN) dropped 4.10% to $6.55 after dropping 6.32% on Thursday.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.